Natural and Recombinant SARS-CoV-2 Isolates Rapidly Evolve In Vitro to Higher Infectivity through More Efficient Binding to Heparan Sulfate and Reduced S1/S2 Cleavage
- PMID: 34406867
- PMCID: PMC8513475
- DOI: 10.1128/JVI.01357-21
Natural and Recombinant SARS-CoV-2 Isolates Rapidly Evolve In Vitro to Higher Infectivity through More Efficient Binding to Heparan Sulfate and Reduced S1/S2 Cleavage
Abstract
One of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virulence factors is the ability to interact with high affinity to the ACE2 receptor, which mediates viral entry into cells. The results of our study demonstrate that within a few passages in cell culture, both the natural isolate of SARS-CoV-2 and the recombinant cDNA-derived variant acquire an additional ability to bind to heparan sulfate (HS). This promotes a primary attachment of viral particles to cells before their further interactions with the ACE2. Interaction with HS is acquired through multiple mechanisms. These include (i) accumulation of point mutations in the N-terminal domain (NTD) of the S protein, which increases the positive charge of the surface of this domain, (ii) insertions into the NTD of heterologous peptides containing positively charged amino acids, and (iii) mutation of the first amino acid downstream of the furin cleavage site. This last mutation affects S protein processing, transforms the unprocessed furin cleavage site into the heparin-binding peptide, and makes viruses less capable of syncytium formation. These viral adaptations result in higher affinity of viral particles to heparin, dramatic increase in plaque sizes, more efficient viral spread, higher infectious titers, and 2 orders of magnitude higher infectivity. The detected adaptations also suggest an active role of NTD in virus attachment and entry. As in the case of other RNA-positive (RNA+) viruses, evolution to HS binding may result in virus attenuation in vivo. IMPORTANCE The spike protein of SARS-CoV-2 is a major determinant of viral pathogenesis. It mediates binding to the ACE2 receptor and, later, fusion of viral envelope and cellular membranes. The results of our study demonstrate that SARS-CoV-2 rapidly evolves during propagation in cultured cells. Its spike protein acquires mutations in the NTD and in the P1' position of the furin cleavage site (FCS). The amino acid substitutions or insertions of short peptides in NTD are closely located on the protein surface and increase its positive charge. They strongly increase affinity of the virus to heparan sulfate, make it dramatically more infectious for the cultured cells, and decrease the genome equivalent to PFU (GE/PFU) ratio by orders of magnitude. The S686G mutation also transforms the FCS into the heparin-binding peptide. Thus, the evolved SARS-CoV-2 variants efficiently use glycosaminoglycans on the cell surface for primary attachment before the high-affinity interaction of the spikes with the ACE2 receptor.
Keywords: ACE2; SARS-CoV-2; coronavirus; furin cleavage; heparin binding; recombinant virus; spike NTD; spike protein; viral evolution.
Figures
Update of
-
Natural isolate and recombinant SARS-CoV-2 rapidly evolve in vitro to higher infectivity through more efficient binding to heparan sulfate and reduced S1/S2 cleavage.bioRxiv [Preprint]. 2021 Jun 29:2021.06.28.450274. doi: 10.1101/2021.06.28.450274. bioRxiv. 2021. Update in: J Virol. 2021 Oct 13;95(21):e0135721. doi: 10.1128/JVI.01357-21. PMID: 34230926 Free PMC article. Updated. Preprint.
Similar articles
-
Acquisition of Furin Cleavage Site and Further SARS-CoV-2 Evolution Change the Mechanisms of Viral Entry, Infection Spread, and Cell Signaling.J Virol. 2022 Aug 10;96(15):e0075322. doi: 10.1128/jvi.00753-22. Epub 2022 Jul 25. J Virol. 2022. PMID: 35876526 Free PMC article.
-
Rapid SARS-CoV-2 Adaptation to Available Cellular Proteases.J Virol. 2022 Mar 9;96(5):e0218621. doi: 10.1128/jvi.02186-21. Epub 2022 Jan 12. J Virol. 2022. PMID: 35019723 Free PMC article.
-
Proteolytic activation of SARS-CoV-2 spike protein.Microbiol Immunol. 2022 Jan;66(1):15-23. doi: 10.1111/1348-0421.12945. Epub 2021 Oct 12. Microbiol Immunol. 2022. PMID: 34561887 Free PMC article. Review.
-
The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.Tumour Biol. 2021;43(1):177-196. doi: 10.3233/TUB-200084. Tumour Biol. 2021. PMID: 34420993 Review.
-
Natural isolate and recombinant SARS-CoV-2 rapidly evolve in vitro to higher infectivity through more efficient binding to heparan sulfate and reduced S1/S2 cleavage.bioRxiv [Preprint]. 2021 Jun 29:2021.06.28.450274. doi: 10.1101/2021.06.28.450274. bioRxiv. 2021. Update in: J Virol. 2021 Oct 13;95(21):e0135721. doi: 10.1128/JVI.01357-21. PMID: 34230926 Free PMC article. Updated. Preprint.
Cited by
-
Comparison of SARS-CoV-2 variants of concern in primary human nasal cultures demonstrates Delta as most cytopathic and Omicron as fastest replicating.mBio. 2024 Apr 10;15(4):e0312923. doi: 10.1128/mbio.03129-23. Epub 2024 Mar 13. mBio. 2024. PMID: 38477472 Free PMC article.
-
The Potential of Usnic-Acid-Based Thiazolo-Thiophenes as Inhibitors of the Main Protease of SARS-CoV-2 Viruses.Viruses. 2024 Jan 31;16(2):215. doi: 10.3390/v16020215. Viruses. 2024. PMID: 38399993 Free PMC article.
-
Endothelial Glycocalyx Injury in SARS-CoV-2 Infection: Molecular Mechanisms and Potential Targeted Therapy.Mediators Inflamm. 2023 Aug 29;2023:6685251. doi: 10.1155/2023/6685251. eCollection 2023. Mediators Inflamm. 2023. PMID: 37674786 Free PMC article. Review.
-
Comparison of SARS-CoV-2 variants of concern in primary human nasal cultures demonstrates Delta as most cytopathic and Omicron as fastest replicating.bioRxiv [Preprint]. 2023 Dec 21:2023.08.24.553565. doi: 10.1101/2023.08.24.553565. bioRxiv. 2023. Update in: mBio. 2024 Apr 10;15(4):e0312923. doi: 10.1128/mbio.03129-23. PMID: 37662273 Free PMC article. Updated. Preprint.
-
All Domains of SARS-CoV-2 nsp1 Determine Translational Shutoff and Cytotoxicity of the Protein.J Virol. 2023 Mar 30;97(3):e0186522. doi: 10.1128/jvi.01865-22. Epub 2023 Feb 27. J Virol. 2023. PMID: 36847528 Free PMC article.
References
-
- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus Investigating and Research Team. 2020. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382:727–733. 10.1056/NEJMoa2001017. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U19AI142737/HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
- R01AI133159/HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
- R01AI118867/HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
- U19 AI142737/AI/NIAID NIH HHS/United States
- R01 AI118867/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous